| Sign In to gain access to subscriptions and/or personal tools. |
Sitagliptin — enhancing incretin actionDiabetic Department, Victoria Hospital, Kirkcaldy, KY2 5AH, Scotland, UK
Diabetes Research Group, School of Life and Health Sciences, Aston University, Aston Triangle, Birmingham, UK, cday{at}mededuk.com DPP-4 inhibition offers a new approach to the treatment of type 2 diabetes. Sitagliptin is the first in this new class of agent that lowers hyperglycaemia mainly via enhancing the action of endogenous incretin hormones. Sitagliptin improves glycaemic control with a low risk of hypoglycaemia or weight gain.
Key Words: DPP-4 gliptin incretin inhibitor sitagliptin type 2 diabetes
The British Journal of Diabetes & Vascular Disease, Vol. 7, No. 3,
134-139 (2007) |
|||